Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clemastine fumarate + dexamethasone is a combination of two pharmaceutical agents used primarily for the treatment of allergic and inflammatory conditions. Clemastine fumarate is a first-generation antihistamine that acts as an antagonist at the histamine H1 receptor, thereby blocking the effects of endogenous histamine and providing relief from symptoms such as sneezing, runny nose, itching, and hives[2][6][8]. Dexamethasone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties; it works by binding to glucocorticoid receptors to inhibit multiple inflammatory cytokines and suppress immune responses[4][5]. This combination may be used in clinical settings where both antihistaminic (for immediate allergy symptom relief) and anti-inflammatory (for reducing swelling or severe allergic reactions) actions are desired. The primary indications include severe allergies or skin conditions such as eczema[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clemastine fumarate + dexamethasone.